移植后需胰岛素治疗的糖尿病识别实体器官移植后高风险结局
PTDM与死亡、移植物失败、排斥、心血管事件、感染、恶性肿瘤及肾脏代谢并发症的长期风险升高相关;需胰岛素治疗的PTDM患者移植物和患者结局显著更差,提示胰岛素需求识别高风险代谢表型。
要点
- PTDM增加实体器官移植后死亡、移植物失败、排斥及心血管事件等长期风险。
- 需胰岛素治疗的PTDM患者结局显著差于非胰岛素治疗者,尽管长期血糖控制相似。
- 应加强移植受者代谢风险分层和个体化管理。
核心结论
- PTDM是实体器官移植后长期结局的慢性修饰因素。
- 需胰岛素治疗的PTDM识别出尤其高风险亚组,需改进代谢风险分层和量身定制的管理策略。
研究设计与样本
- 分析TriNetX全球协作网络(2006-2024)中无既往糖尿病的成人实体器官移植受者。
- 采用时间至事件分析评估PTDM发病率和危险因素。
- 采用倾向评分匹配队列评估临床结局。
- 采用治疗路径分析描述抗糖尿病治疗模式,并比较胰岛素与非胰岛素为基础的管理。
主要发现
- PTDM发病率随时间增加,且随移植器官、移植年代和地理区域显著变化。
- 年龄较大、男性、肥胖、基线血糖异常、血脂异常、肾功能减退和免疫抑制暴露与PTDM独立相关。
- 匹配后,PTDM与死亡、移植物失败、移植物排斥、心血管事件、感染、恶性肿瘤和肾脏代谢并发症的长期风险升高相关,而早期移植后风险基本相当。
- 抗糖尿病治疗模式异质且器官特异性。
- 胰岛素治疗的PTDM受者移植物和患者结局显著差于非胰岛素治疗者,尽管长期血糖控制相似,提示胰岛素需求识别高风险代谢表型。
临床怎么用
- 对实体器官移植受者应监测PTDM发生,尤其具备年龄较大、男性、肥胖、基线血糖异常、血脂异常、肾功能减退和免疫抑制暴露等危险因素者。
- 对需胰岛素治疗的PTDM患者应识别为高风险亚组,加强代谢风险分层和个体化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Post-transplant diabetes mellitus (PTDM) is a common complication after solid organ transplantation, but its long-term prognostic significance and the clinical implications of post-transplant antidiabetic treatment patterns remain incompletely understood. We aimed to evaluate PTDM incidence, determinants, treatment patterns, and associated long-term outcomes using large-scale real-world data. METHODS: We analyzed adult solid organ transplant recipients without preexisting diabetes within the TriNetX Global Collaborative Network (2006-2024). PTDM incidence and risk factors were assessed using time-to-event analyses. Clinical outcomes were evaluated using propensity score-matched cohorts. Antidiabetic treatment patterns were characterized using treatment pathway analyses and outcomes were compared according to insulin vs non-insulin-based management among recipients with PTDM. RESULTS: Among 263 325 recipients, PTDM incidence increased over time and varied markedly by transplanted organ, transplant era, and geographic region. Older age, male sex, adiposity, baseline dysglycemia, dyslipidemia, reduced renal function, and immunosuppressive exposure were independently associated with PTDM. After matching, PTDM was associated with higher long-term risks of mortality, graft failure, graft rejection, cardiovascular events, infections, malignancies, and renal-metabolic complications, whereas early post-transplant risks were largely comparable. Antidiabetic treatment patterns were heterogeneous and organ-specific. Insulin-treated PTDM recipients experienced substantially worse graft and patient outcomes than non-insulin-treated recipients, despite similar long-term glycemic control, indicating that insulin requirement identifies a high-risk metabolic phenotype. Findings were consistent in single organ transplant-specific sensitivity analyses. CONCLUSION/INTERPRETATION: PTDM acts as a chronic modifier of long-term outcomes after solid organ transplantation. Insulin-treated PTDM identifies a subgroup at particularly high risk, underscoring the need for improved metabolic risk stratification and tailored management strategies in transplant recipients.
引用
- Caldara R, Catarinella D, Gremizzi C, et al. Post-transplant diabetes mellitus requiring insulin identifies high-risk outcomes after solid organ transplantation. J Clin Endocrinol Metab. 2026. PMID: 42186204. doi:10.1210/clinem/dgag217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。